Episode 8: Macro outlook, Microcap investing & Scorecard review

Shares in med-tech developer Polynovo (ASX:PNV) have doubled in the past year, driven by surging sales in its patented Novosorb product. More recently, the company revealed its first “million dollar month”, with sales for April ostensibly bringing the business to break-even on a monthly basis. What does the business do? Following a business restructure in 2014, Polynovo is focused on […]

Join us as we chat about the wild, weird, and whacky of small cap investing, all while searching for those precious few fast-growing businesses that have a shot of becoming industry giants. You can find the full catalogue on the Baby Giants website, on Spotify, or anywhere good podcasts are found. Also, be sure to follow us on twitter. © […]

Your ego is your worst investment adviser. A simple notebook — or a few honest Straws — might just be your most valuable portfolio tool.

There’s a growing sense of discontent today, and not unreasonably so for those who feel the system has let them down. And, let’s be real, it has let a great many people down. Unless you have outsized earning power, or have built up a decent portfolio of assets, life is getting increasingly difficult. And even if you do, life isn’t […]

The concept of ‘value’ is core to investing. At one level, it’s a relatively straightforward idea, and one we intuitively understand. As investors, we are, essentially, trying to buy assets for less than what they are “really” worth. For us, the value is captured when the wider market recognises and corrects the mispricing. But there’s also value in something that is (somehow) perfectly […]

As the manic rhythm of the ASX begins to settle into its annual summer slumber, it’s a good time to step back from the screens and recharge our batteries. To that end, we’ll be taking a short break from our regular weekly correspondence over the coming weeks as we look to refresh and prepare for the year ahead. While the […]

Company earnings drive share prices over the longer term. More specifically, earnings per share, or EPS, does. It’s the great attractor that ultimately pulls prices along. You won’t find a single example of a company, ever, that has compounded its stock price over decades without also compounding EPS. It just doesn’t happen. That’s why EPS should sit at the centre of […]